BSX vs IRTC: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
BSX is the larger of the two ($69.46B market cap): the incumbent the market prices for continued execution (13.57x forward earnings, beta 0.58). IRTC is the smaller challenger ($3.85B), actually pricier on forward earnings (108.35x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
BSX vs IRTC: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BSX | IRTC | What it tells you |
|---|---|---|---|
| Market cap | $69.46B | $3.85B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 13.57 | 108.35 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.58 | 1.27 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 7% of range | 15% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 2.69 | 23.88 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: BSX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how BSX and IRTC affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BSX and IRTC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BSX and IRTC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Boston Scientific Corporation (BSX) do?
Boston Scientific Corporation is a Marlborough, Massachusetts-based medical device company that develops, manufactures, and markets minimally invasive devices used in interventional cardiology, electrophysiology, structural heart, peripheral interventions, endoscopy, urology, neuromodulation, and cardiac rhythm management. It reports through two broad segments: Cardiovascular, which houses the fast-growing electrophysiology business (led by the Farapulse pulsed field ablation system) and the Watchman left-atrial-appendage closure franchise, and MedSurg, which spans endoscopy, urology, and neuromodulation. The company sells into hospitals and physicians across roughly 130 countries and competes at the leading edge of catheter-based and device-based procedures that substitute for more invasive surgery.
What does iRhythm Technologies (IRTC) do?
iRhythm Technologies makes the Zio service, a small adhesive patch that records a patient's heart rhythm continuously for up to 14 days and pairs it with AI-assisted analysis to detect arrhythmias such as atrial fibrillation. The device replaced the older Holter-monitor workflow (short-window, wired recorders) with a longer, more comfortable, water-resistant patch that is mailed back for algorithmic analysis and a physician report. Zio has become the most widely prescribed ambulatory ECG monitor in the US, and iRhythm is extending the franchise with a next-generation mobile cardiac telemetry platform (Zio MCT), international expansion, and adjacencies such as sleep apnea and primary-care risk stratification.
BSX vs IRTC: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- BSX drivers: Farapulse and the Pulsed Field Ablation Wave; Watchman Franchise Expansion.
- IRTC drivers: Zio volume growth and category leadership; Next-generation Zio MCT and AI.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The most immediate concern flagged with 2026 guidance was unanticipated headwinds in electrophysiology, Watchman, and urology, which prompted management to frame organic growth guidance of 6.5% to 8%, below the pace of recent years and a signal that the newest franchises may be decelerating from peak growth rates. For IRTC, regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT.
BSX or IRTC: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BSX if you believe its drivers more; IRTC if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BSX and IRTC guides.
BSX vs IRTC: the full fundamentals
BSX. Boston Scientific's trailing P/E of roughly 18x sits well below the peer-group average of roughly 34x cited by valuation trackers, a reversal from the sustained premium multiple the stock carried during its high-growth phase. The compression followed a steep share-price decline over the trailing year that coincided with a downward revision to organic growth guidance and disappointing signals in electrophysiology, Watchman, and urology. Net profit margin runs near 17%, and full-year 2026 adjusted EPS growth is guided to 9% to 11%, so the debate is whether the lower multiple reflects fair concern about decelerating growth or an over-correction relative to the franchise's still-double-digit earnings trajectory.
IRTC. IRTC trades at a premium price-to-sales multiple (roughly $4 billion of market value on under $1 billion of trailing revenue), typical of a high-growth medtech that is still scaling toward consistent GAAP profitability. The company is adjusted-EBITDA positive and guides to a 12% to 13% adjusted-EBITDA margin for 2026, but it still posts GAAP net losses. The valuation therefore leans heavily on continued volume growth and margin expansion rather than current earnings.
Headline figures (approximate, July 2026): BSX shows revenue (ttm) ~$20.6 billion, revenue (fy 2025) ~$20 billion, q1 2026 revenue ~$5.2 billion (+11.6% YoY reported, ~9.4% organic), adjusted eps guidance (fy 2026) ~$3.34 to $3.41 (9% to 11% growth); IRTC shows revenue (ttm) ~$790M, q1 2026 revenue growth ~26% YoY, gross margin ~71%, fy2026 revenue guidance ~$875M-$885M.
The bottom line: BSX vs IRTC
BSX and IRTC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BSX and IRTC exposure against your real portfolio. It is not an investment adviser.
Wondering how BSX or IRTC fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Boston Scientific Corporation with AI
Connect the broker you already use and ask Walnut's AI how BSX fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between BSX and IRTC?
+
Boston Scientific Corporation is a Marlborough, Massachusetts-based medical device company that develops, manufactures, and markets minimally invasive devices used in interventional cardiology, electrophysiology, structural heart, peripheral interventions, endoscopy, urology, neuromodulation, and cardiac rhythm management. iRhythm Technologies makes the Zio service, a small adhesive patch that records a patient's heart rhythm continuously for up to 14 days and pairs it with AI-assisted analysis to detect arrhythmias such as atrial fibrillation. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BSX or IRTC the better stock?
+
Neither is universally better. BSX is the larger incumbent; IRTC is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BSX or IRTC?
+
On forward P/E (as of August 2026), BSX trades at 13.57x and IRTC at 108.35x, so BSX is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BSX and IRTC?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BSX vs IRTC?
+
BSX: The most immediate concern flagged with 2026 guidance was unanticipated headwinds in electrophysiology, Watchman, and urology, which prompted management to frame organic growth guidance of 6.5% to 8%, below the pace of recent years and a signal that the newest franchises may be decelerating from peak growth rates. Competition is intensifying as Medtronic and Johnson and Johnson scale their own pulsed field ablation systems, which could erode Boston Scientific's early PFA share and pressure pricing. The stock has historically carried a premium valuation, so any slowdown in the growth narrative can trigger outsized share-price reactions, as seen in a sharp post-earnings selloff. Foreign exchange swings, hospital capital-spending cycles, product-recall or safety-signal risk inherent to implantable devices, and reimbursement or regulatory changes each add uncertainty. Integration risk from the company's ongoing acquisition strategy is a further variable that can affect margins and management focus. IRTC: Regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT. Reimbursement is the other central risk, since a large share of revenue depends on CMS and commercial payer rates that can be cut or restructured. The company still reports GAAP net losses and trades at a premium revenue multiple, so any volume slowdown, pricing pressure, or launch delay could compress the stock sharply. Competition from larger, better-capitalized players (Philips, Boston Scientific) and the possibility of equity issuance under a shelf registration add further risk. Investors should size positions with the understanding that medtech reimbursement and regulatory outcomes are difficult to predict.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BSX or IRTC; figures are approximate and dated (as of August 2026). Verify current data before investing.